Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II allogeneic stem cell transplantation from alternative donors in active acute leukemia
2012-004008-37Phase 2Completed
- Sponsor
- GITMO
- Start
- May 2013
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of thiotepa, busulfan, fludarabine and micafungin in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) (3 arms), sponsored by GITMO. Primary endpoint: Overall survival at 2 years. Started May 2013; status: completed.
02
Drugs
thiotepabusulfanfludarabinemicafungin
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2012-004008-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004008-37.